MHRA statement on SGLT2s during Covid
COVID-19: Use of SGLT2s in Diabetes (Dapagliflozin/Canagliflozin/Empagliflozin/Ertugliflozin The MHRA have advised that SGLT2 inhibitor treatment should be interrupted in patients who are hospitalised for majorsurgical...
Read More